In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect.
We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, based on various allegations of legal liability concerning the potential increased risk of T-cell lymphoma:
- Defendants Regeneron and Sanofi knew or should have known of the potential of Dupixent to exacerbate or accelerate pre-existing T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), or increase susceptibility to its development.
- Defendants failed to adequately test Dupixent to investigate the risks, including the potential of exacerbating pre-existing T-cell lymphoma or increasing susceptibility to its development.
- Defendants failed to warn physicians and patients that Dupixent should not be prescribed or administered to patients with confirmed or suspected T-cell lymphoma, including CTCL and PTCL.
Next, we provide some medical information about T-cell lymphoma:
- There are several types of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
- CTCL is a T-cell lymphoma that begins in the skin. Mycosis fungoides and Sézary syndrome are the two most common subtypes of CTCL.
- PTCL refers to systemic T-cell lymphomas that are found in the lymph nodes, other organs, and the blood. Also, some types involve the skin.
- T-cell lymphomas, both CTCL and PTCL, are a subtype of non-Hodgkin lymphoma (NHL).
We are currently investigating possible Dupixent legal compensation cases for patients who were diagnosed with one of more types of T-cell lymphona some time after they started using Dupixent.
For those patients, we encourage you to submit a Dupixent Cancer Case Evaluation Form online — it is free, confidential, and there is no obligation. You will get a reply from us no later than the next business day. Or call attorney Tom Lamb at 910-256-2971 to discuss their potential Dupixent legal case.
Dupixent
Free Case Evaluation
Strictly Confidential, No Obligation